Hims & Hers Health (NYSE:HIMS) Shares Gap Down on Insider Selling

Hims & Hers Health, Inc. (NYSE:HIMS) shares gapped down prior to trading on Thursday after an insider sold shares in the company. The stock had previously closed at $26.95, but opened at $25.16. Hims & Hers Health shares last traded at $26.27, with a volume of 6,054,360 shares traded.

Specifically, CFO Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock in a transaction dated Tuesday, April 15th. The stock was sold at an average price of $28.50, for a total transaction of $330,058.50. Following the completion of the sale, the chief financial officer now owns 118,960 shares of the company’s stock, valued at $3,390,360. The trade was a 8.87 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Soleil Boughton sold 3,236 shares of Hims & Hers Health stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $28.72, for a total transaction of $92,937.92. Following the sale, the insider now owns 162,898 shares of the company’s stock, valued at approximately $4,678,430.56. The trade was a 1.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In related news, insider Soleil Boughton sold 4,151 shares of the firm’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $45.14, for a total transaction of $187,376.14. Following the completion of the transaction, the insider now owns 166,134 shares of the company’s stock, valued at $7,499,288.76. This trade represents a 2.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Bank of America upped their price target on shares of Hims & Hers Health from $21.00 to $22.00 and gave the company an “underperform” rating in a report on Tuesday, March 18th. Needham & Company LLC raised their target price on Hims & Hers Health from $31.00 to $61.00 and gave the stock a “buy” rating in a report on Tuesday, February 25th. Canaccord Genuity Group boosted their price target on Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday, February 19th. Piper Sandler raised their price objective on shares of Hims & Hers Health from $24.00 to $35.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 25th. Finally, Citigroup reaffirmed a “sell” rating on shares of Hims & Hers Health in a report on Wednesday, April 2nd. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $38.25.

Hims & Hers Health Price Performance

The business’s 50 day moving average price is $37.59 and its 200 day moving average price is $30.56. The firm has a market cap of $6.05 billion, a PE ratio of 61.91 and a beta of 1.65.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.02. The business had revenue of $481.14 million during the quarter, compared to analysts’ expectations of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. As a group, analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Institutional Investors Weigh In On Hims & Hers Health

Several institutional investors and hedge funds have recently added to or reduced their stakes in HIMS. SlateStone Wealth LLC raised its position in shares of Hims & Hers Health by 4.0% in the fourth quarter. SlateStone Wealth LLC now owns 10,640 shares of the company’s stock valued at $257,000 after buying an additional 413 shares during the last quarter. Blume Capital Management Inc. raised its holdings in Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 600 shares during the last quarter. Summit Investment Advisors Inc. raised its holdings in Hims & Hers Health by 3.3% in the 4th quarter. Summit Investment Advisors Inc. now owns 19,853 shares of the company’s stock valued at $480,000 after acquiring an additional 628 shares during the last quarter. Cim LLC lifted its stake in Hims & Hers Health by 1.0% in the 4th quarter. Cim LLC now owns 71,869 shares of the company’s stock worth $1,738,000 after purchasing an additional 694 shares in the last quarter. Finally, Harbour Investments Inc. boosted its holdings in shares of Hims & Hers Health by 18.8% during the 4th quarter. Harbour Investments Inc. now owns 5,269 shares of the company’s stock worth $127,000 after purchasing an additional 833 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.